Global Hereditary Angioedema Market to Reach $3.9 Billion by 2027
Amid the COVID-19 crisis, the global market for Hereditary Angioedema estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.9 Billion by 2027, growing at a CAGR of 7.8% over the analysis period 2020-2027. C1 Esterase Inhibitor, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Selective Bradykinin B2 Receptor Antagonist segment is readjusted to a revised 6.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $690.1 Million, While China is Forecast to Grow at 7.2% CAGR
The Hereditary Angioedema market in the U.S. is estimated at US$690.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$683.6 Million by the year 2027 trailing a CAGR of 7.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 6.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.
Kallikrein Inhibitor Segment to Record 7.4% CAGR
In the global Kallikrein Inhibitor segment, USA, Canada, Japan, China and Europe will drive the 7.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.6 Million in the year 2020 will reach a projected size of US$149.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$451.7 Million by the year 2027.
Select Competitors (Total 46 Featured):
Amid the COVID-19 crisis, the global market for Hereditary Angioedema estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.9 Billion by 2027, growing at a CAGR of 7.8% over the analysis period 2020-2027. C1 Esterase Inhibitor, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Selective Bradykinin B2 Receptor Antagonist segment is readjusted to a revised 6.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $690.1 Million, While China is Forecast to Grow at 7.2% CAGR
The Hereditary Angioedema market in the U.S. is estimated at US$690.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$683.6 Million by the year 2027 trailing a CAGR of 7.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 6.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.
Kallikrein Inhibitor Segment to Record 7.4% CAGR
In the global Kallikrein Inhibitor segment, USA, Canada, Japan, China and Europe will drive the 7.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.6 Million in the year 2020 will reach a projected size of US$149.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$451.7 Million by the year 2027.
Select Competitors (Total 46 Featured):
- BioCryst Pharmaceuticals, Inc.
- CSL Ltd.
- iBio, Inc.
- Ionis Pharmaceuticals, Inc.
- Pharming Group NV
- Shire PLC
Frequently Asked Questions about the Global Market for Hereditary Angioedema
What is the estimated value of the Global Market for Hereditary Angioedema?
What is the growth rate of the Global Market for Hereditary Angioedema?
What is the forecasted size of the Global Market for Hereditary Angioedema?
| Report Attribute | Details |
|---|---|
| No. of Pages | 232 |
| Published | April 2021 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD ) in 2020 | $ 2.3 Billion |
| Forecasted Market Value ( USD ) by 2027 | $ 3.9 Billion |
| Compound Annual Growth Rate | 7.8% |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE
1. MARKET OVERVIEW
III. MARKET ANALYSIS
IV. COMPETITION
